// App-Quantinova.ai

P035 : Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease

Researchers

Presenter

  • A Lewis

Principal Investigators

  • A Nijhuis

  • G Berti

  • C L Bishop

  • R Feakins

  • J O Lindsay

  • A Silver

Medical Centers

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Genomics and Child Health, London, UK

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Cell Biology and Cutaneous Research, London, UK

  • Department of Histopathology, The Royal London Hospital, London, UK

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Transforming growth factor beta

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved